Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bicara TherapeuticsBCAX +2.40%14 Price-to-Tangible-Book is 3.33 as of Sep. 08, 2026. GuruFocus rates BCAX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,127 Biotechnology companies, Bicara Therapeutics ranks better than 51.02% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Bicara Therapeutics Price-to-Tangible-Book Related Terms
Bicara Therapeutics Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Bicara Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BCAX vs LTGO, LBRX, AVLN: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Bicara Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicara Therapeutics Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Bicara Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Bicara Therapeutics (BCAX) has a Price-to-Tangible-Book of 3.33 as of Sep. 08, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Bicara Therapeutics and its competitors. According to the industry distribution chart, Bicara Therapeutics ranks #552 out of 1127 companies in the Biotechnology industry, placing it in the top 49%.
Is Bicara Therapeutics' Price-to-Tangible-Book too high?
Bicara Therapeutics' current Price-to-Tangible-Book is 3.33. The Biotechnology industry median Price-to-Tangible-Book is 3.38. Bicara Therapeutics' value of 3.33 is 1.5% below this industry median. Based on the distribution chart, Bicara Therapeutics ranks #552 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bicara Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Price-to-Tangible-Book compare to LTGO and LBRX?
According to the Biotechnology industry distribution chart, Bicara Therapeutics ranks #552 out of 1127 companies for Price-to-Tangible-Book. This puts Bicara Therapeutics in the upper half of its industry. The industry median Price-to-Tangible-Book is 3.38. Bicara Therapeutics' value of 3.33 is 1.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.38, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bicara Therapeutics's current Price-to-Tangible-Book of 3.33 is 1.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Bicara Therapeutics and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicara Therapeutics's current Price-to-Tangible-Book is 3.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Price-to-Tangible-Book of 3.33. The current Price-to-Tangible-Book is 3.33 and 1.5% below the Biotechnology industry median of 3.38. Bicara Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Price-to-Tangible-Book is 3.33 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
14GF Score
Get the complete analysis for BCAX
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCAX has been successfully added to your 
